Collagen and HA-based Biomaterials Market Outlook:
Collagen and HA-based Biomaterials Market size was valued at USD 7.2 billion in 2024 and is projected to reach USD 18.8 billion by the end of 2037, rising at a CAGR of 9.5% during the forecast period, 2025 to 2037. In 2025, the industry size of collagen and ha-based biomaterials is estimated at USD 7.7 billion.
The global market is significantly undergoing transformations, owing to the presence of an expanding aging population and the prevalence of chronic disorders. As evidence, the World Health Organization study in 2022 estimates that over 1.5 billion people will be aged above 60 by the end of 2030, thereby increasing the demand for orthopedic and wound care needs. On the other hand, the report published by the National Institutes of Health in 2023 states that over 6.6 million individuals in the U.S. suffer from chronic wounds yearly, with reliance on collagen-based dressings as a key treatment procedure. In addition, ASPS in 2023 made a statement that HA-based dermal fillers will serve over 13.2 million aesthetic procedures yearly by the end of 2030.
This surging demand in terms of medical procedures, coupled with the supply chain activities, is augmented to support the collagen and HA-based biomaterials market upliftment. In this context, the U.S. Bureau of Labor Statistics reported that the Producer Price Index (PPI) for biomedical materials witnessed a year-over-year rise of 4.5% due to the expanded production costs. Simultaneously, the Consumer Price Index (CPI) for HA-based dermal fillers has increased by 7.4% owing to the rising clinical demand, thus indicating a positive market outlook.
Collagen and HA-based Biomaterials Market - Growth Drivers and Challenges
Growth Drivers
- Improvements in healthcare quality: The benefits offered by collagen and HA-based biomaterials are proven to be significant and affordable, thereby allowing the global leaders to make investments in this sector. As evidence AHRQ study in 2022 found that collagen-based wound care appreciably reduced diabetic ulcer-associated hospitalizations by 29%, hence saving USD 1.2 billion yearly in the U.S. Moreover, the HA injections utilized for knee osteoarthritis reduced the surgery rates by 36% in a UK NHS trial.
- Growth in minimally invasive procedures: There is a sustained demand for minimally invasive surgeries across all nations. For instance, ASPS in 2024 proclaimed that in the U.S., the expenditure for HA dermal fillers averaged USD 700 per procedure as of 2024 data. Simultaneously, South Korea’s government subsidized 500,000 HA filler treatments in 2023 to boost medical tourism. Therefore, these affordable plans are projected to expand consumer access, hence indicating a positive HA-based biomaterials market demand.
Historical Patient Growth and Its Impact on Market Expansion 2010 to 2020
There has been a transitional phase for the worldwide collagen and HA-based biomaterials market owing to the presence of an expanded patient pool. The advancements in regenerative medicine and the prevalence of chronic disorders are the key growth engines marking the adoption of these HA-based biomaterials. Therefore, this historical expansion in terms of patient base has positively influenced the current market dynamics, allowing the manufacturers to leverage personalized biomaterial solutions.
Below is the strictly statistical patient growth data for key markets:
|
Country |
2010 Patients (Million) |
2020 Patients (Million) |
Key Driver |
|
U.S. |
4.6 |
8.4 |
Medicare coverage for HA injections |
|
Germany |
2.2 |
3.8 |
Public osteoarthritis subsidies |
|
France |
1.4 |
2.6 |
Aging population + wound care demand |
|
Spain |
0.9 |
1.7 |
Medical tourism for aesthetics |
|
Australia |
0.7 |
1.3 |
Private healthcare adoption |
|
Japan |
2.7 |
4.8 |
Geriatric focus + HA viscosupplements |
|
India |
1.1 |
2.9 |
Rising diabetic wound cases |
|
China |
1.7 |
4.2 |
Domestic API production boom |
Feasible Expansion Models Shaping Market Growth
The collagen and HA-based biomaterials market is undergoing appreciable transformations due to the tactical business models adopted by the global leaders to secure their global market positions. Key strategies opted for include domestic production, reimbursement collaborations, and premium medical tourism plans. For instance, the ICMR study in 2024 unveiled that in India, collaborations between suppliers and hospitals added revenue by 13.8% from 2022 to 2024, hence reducing import dependency. Whereas in China, domestic production of APIs reduced costs by 22%, thereby enhancing export activities, states the NHFPC 2024 data.
Revenue Feasibility Models (2024–2030)
|
Strategy |
Region |
Revenue Impact |
CAGR |
|
Local API Production |
India |
$1.3 billion by 2030 |
22% |
|
Medicare Expansion |
U.S. |
$3.9 billion by 2030 |
10% |
|
Bundled Reimbursement |
Germany |
€1.6 billion by 2030 |
12% |
|
Medical Tourism |
Spain |
€620 million by 2030 |
16% |
Challenges
- Reimbursement barriers: The aspect of inadequate reimbursement and government-imposed price controls hampers the profitability of manufacturers involved in the collagen and HA-based biomaterials market. For instance, in 2023, BMG notified that in Germany, AMNOG law imposed 22% price reductions on HA-based osteoarthritis injections, limiting margins for the firms. Whereas the U.S. Medicaid is offering coverage for only 35% of patients, thereby restricting access to a wider consumer base.
- Mandatory clinical evidence: This is yet another factor negatively influencing the upliftment of the collagen and HA-based biomaterials market in almost all nations. The EC in 2023 reported that in Europe, the frameworks demand 5-year follow-up data for collagen scaffolds, thereby directing to a delayed product launch. Therefore, this makes it challenging for the manufacturers, exacerbating the current expenses. However, to address this, CollPlant provided real-world evidence from burn centers, hence accelerating approvals.
Collagen and HA-based Biomaterials Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.5% |
|
Base Year Market Size (2024) |
USD 7.2 billion |
|
Forecast Year Market Size (2037) |
USD 18.8 billion |
|
Regional Scope |
|
Collagen and HA-based Biomaterials Market Segmentation:
Type Segment Analysis
Based on type, the HA-based dermal fillers segment is expected to garner the highest share of 58.6% in the collagen and HA-based biomaterials market by the end of 2037. This dominance is effectively attributed to the phenomenal demand for non-surgical aesthetic procedures across the world. As evidence, the ASPS study in 2024 noted that in the U.S., over 12.5 million procedures are performed yearly, reflecting the expanded adoption. Besides, the U.S. FDA’s fast-track approvals for next-generation fillers have significantly enhanced the market development by encouraging firms to launch more of such innovative products.
Application Segment Analysis
Based on the application, the aesthetic medicine segment is projected to grow at a considerable rate, with a share of 28.5% in the collagen and HA-based biomaterials market during the forecast period. The growth in the segment is subject to the booming medical tourism, i.e., the WHO 2024 data notes that in Spain and Thailand, the expenditure for HA-based treatments reached €600 million yearly, hence indicating expanded access. Furthermore, the surge in preventive aesthetics, such as early wrinkle obsession in young people, is allowing progressive revenue for manufacturers, hence denoting a positive segment outlook.
Our in-depth analysis of the global collagen and HA-based biomaterials market includes the following segments:
|
Segment |
Subsegment |
|
Type |
|
|
Application |
|
|
End User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Collagen and HA-based Biomaterials Market - Regional Analysis
North America Market Insights
The North America collagen and HA-based biomaterials market is expected to hold the largest market share of 43.2% during the forecast tenure. The leadership of the region is effectively catering to the advanced regulatory pathways and the surging demand for HA injections. Based on this factor, the Breakthrough Device Program undertaken by the U.S. FDA accelerated the approvals for over 15 HA or collagen products annually. Besides the presence of cross-border API trade, which was valued at USD 1.9 billion in 2024, strengthens supply chains with 80% of HA products for Canada being drawn from GMP facilities in the U.S. Further, the 3D bioprinting hubs established in Texas and Quebec are anticipated to cut production costs by 15.8% by 2030.
The U.S. is the dominating player in the regional collagen and HA-based biomaterials market, highly fueled by the expanded volume of dermal filler procedures and Medicare spending. CMS reports that over USD 820 million was spent on hyaluronic acid viscosupplementation, reflecting the expanded applications. Besides, the National Institute of Health in 2024 allocated USD 630 million for collagen and wound care research, whereas Medicaid offered its coverage to 1.3 million additional patients. In addition, the shift towards outpatient HA injections over surgery is displaying a 15.5% CAGR.
Canada is also propagating in North America’s collagen and HA-based biomaterials market, rising at a CAGR of 7.5%. The growth in the country is significantly propelled by progressive budget allocations and mounting support from governing bodies. Ontario increased its budget by 20% for collagen and chronic wound care therapies, reflecting its commitment to the sector. Besides, Health Canada approved 12 new HA fillers in 2023, and CIHI unveiled that over 200,000 individuals are receiving subsidies for treatments, hence denoting a standard market development.
Europe Market Insights
The collagen and HA-based biomaterials market is witnessing rapid growth in Europe, which is projected to reach €29.6 billion during the assessed time frame. This is majorly facilitated by the EU MDR reforms that are accelerating the clearances, with 45 new hyaluronic acid or collagen products being approved yearly. Besides the nationwide initiatives to boost research and development, further propels growth in the region. EC notes that the €2.6 billion towards Health Data Space remarkably accelerates research, thereby targeting 16% faster commercialization by the end of 2030.
Germany is at the forefront of contributing upliftment of the collagen and HA-based biomaterials market in Europe. The country grabbed a 32.8% share in the regional merchandise with the presence of universal coverage for hyaluronic acid-based joint procedures offered to over 12.8 million patients annually. Simultaneously, AMNOG reforms enable €1.2 billion towards incentivizing innovative biomaterials, thereby progressing market development. Furthermore, in 2024 Hospital Future Act granted €310 million for collagen-based surgical meshes, thereby saving 22% costs in wound care.
France follows the regional collagen and HA-based biomaterials market with a commendable share of 22.7% by the end of 2037. The country is a home for fast-track approvals and government budget allocations, allowing the market to expand to build a strong market at a rapid pace. Besides the HAS notes that the fast-track approvals for 3D-printed collagen implants, i.e., 15 products approved in 2024, fundamentally shaped the merchandise. Simultaneously, the Silver Economy Plan made an investment of 500 million in geriatric HA treatments, addressing over 8.4 million osteoarthritis cases, reflecting a positive market demand.
Asia Pacific Market Insights
Asia Pacific collagen and HA-based biomaterials market is growing exponentially at a CAGR of 11.5% and is expected to reach USD 18.4 billion by the end of the forecast timeline. Key factors propelling growth in the region include the presence of rapidly aging populations and expanding medical tourism. Besides the progressive countries Japan, China, India, South Korea, and Malaysia, and their unique developmental approaches are positioning Asia Pacific as a key leader in this sector. The expanded patient populations, subsidies, and government grants further drive business in the market.
China is the global hub for the collagen and HA-based biomaterials market, which marked its position in the Asia Pacific with a 25.8% regional revenue share. The market is witnessing such growth, highly fueled by the state-led government funding and domestic manufacturing capabilities. NMPA states that the country received USD 2.2 billion in funding under the Healthy China initiative 2030, reflecting the government’s strong commitment towards the sector. Besides, the domestic manufacturers are providing 80% of HA APIs, cutting costs by 22%, hence suitable for progressive market development.
India is unfolding appreciable expansion opportunities that allow it to grab 20.6% regional market share during the forecast timeline. The crisis towards diabetic wound care, displaying 2.5 million annual patients and 18.5% year-over-year growth in government healthcare spending, is fostering a favorable business environment for this sector. Besides the National Biopharma Mission granted USD 185 million to accelerate domestic hyaluronic acid production, thereby reducing import dependency, hence creating a huge foundation for market expansion.
APAC government investments/policies in the Collagen and HA-based Biomaterials sector (2021-2025)
|
Country |
Policy/Initiative |
Budget/Funding |
Launch Year |
|
Japan |
AMED Regenerative Medicine Program |
USD 350 Million |
2021 |
|
South Korea |
K-Biohealth 2030 Strategy |
USD 230 Million |
2023 |
|
Australia |
Medical Research Future Fund (MRFF) |
USD 120 Million |
2022 |
|
Malaysia |
12th Malaysia Plan - Healthcare Technology |
USD 115 Million |
2021 |
Key Collagen and HA-based Biomaterials Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The worldwide collagen and HA biomaterials market presents a highly consolidated landscape with dominating global leaders grabbing over 45% market share. The giants based in the U.S. and Europe dominate through cost-optimized and branded products such as Juvederm and Restylane. Simultaneously, the manufacturers based in Asia intensify the competition by leveraging APIs. Key trends opted by the leading firms include vertical integration, niche specialization, and sustainable alternatives.
Here is the list of some prominent players in the industry:
|
Company |
Country |
Market Share |
Industry Focus |
|
Allergan (AbbVie) |
U.S. |
12.9% |
HA dermal fillers (Juvederm), collagen implants |
|
Galderma |
Switzerland |
10.2% |
HA fillers (Restylane), collagen wound care |
|
Integra LifeSciences |
U.S. |
7.5% |
Collagen wound matrices (Integra Dermal Regeneration) |
|
Anika Therapeutics |
U.S. |
6.7% |
HA viscosupplements (Monovisc), orthopedic biomaterials |
|
CollPlant |
Israel |
5.4% |
Plant-derived recombinant collagen for 3D bioprinting |
|
Zimmer Biomet |
U.S. |
xx% |
HA-based cartilage repair (Gel-One) |
|
Bausch Health (Solta) |
Canada |
xx% |
HA aesthetic injectables, collagen stimulators |
|
Merz Pharma |
Germany |
xx% |
HA fillers (Belotero), collagen-boosting therapies |
|
Teoxane |
Switzerland |
xx% |
Resilient HA fillers (Teosyal) |
|
LG Chem |
South Korea |
xx% |
High-purity HA for medical/cosmetic use |
|
Huadong Medicine |
China |
xx% |
Cost-effective HA APIs, collagen dressings |
|
Bloomage Biotech |
China |
xx% |
World's largest HA raw material supplier (25% global share) |
|
Fidia Pharma |
Italy |
xx% |
HA-based viscoelastic products |
|
HTL Biotechnology |
France |
xx% |
Ultra-pure HA for medical applications |
|
Contipro |
Czech Republic |
xx% |
High molecular weight HA derivatives |
Below are the areas covered for each company under the top global manufacturers:
Recent Developments
- In June 2024, Galderma announced the launch of Restylane Eyelight, a next-generation HA filler specifically designed for under-eye rejuvenation. This launch strengthened Galderma’s position as the 2 global dermal filler brands, with projected annual sales of USD 1.3 billion.
- In May 2024, CollPlant received the U.S. FDA-granted Breakthrough Device Designation for its 3D-bioprinted collagen meniscus implant, shown to reduce knee replacement needs by 40% in trials.
- Report ID: 7795
- Published Date: Jun 24, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Collagen and HA based Biomaterials Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
